, Volume 175, Issue 1–2, pp 75–82 | Cite as

Onychomycosis Due to Neoscytalidium Treated with Oral Terbinafine, Ciclopirox Nail Lacquer and Nail Abrasion: A Pilot Study of 25 Patients

  • Ígor B. Cursi
  • Roberta Teixeira Silva
  • Isabella Brasil Succi
  • Andréa R. Bernardes-Engemann
  • Rosane Orofino-CostaEmail author



Onychomycosis by Neoscytalidium constitutes chronic infection of the nails, and its frequency has increased in recent decades. Currently, no effective standard treatment exists and literature data remain scarce. This work aimed to conduct a pilot project of combined treatment for this infection.


Thirty patients were divided into three treatment groups: oral terbinafine plus ciclopirox nail lacquer twice a week; ciclopirox nail lacquer twice a week; and ciclopirox nail lacquer 5 days a week, all associated with nail abrasion when required, for 12 months, with 6 months posttreatment follow-up. Clinical and mycological criteria were used for evaluation.


Twenty-five patients completed the study. Significant clinical lesion reduction in disease occurred in all three treatment groups: 21 patients (84 %) entered the study with more than 50 % of diseased nail plate, at the end of treatment, and at 6-month follow-up, 84 and 96 %, respectively, presented less than 25 % nail lesion. Negative microscopy was observed in 36 % of the patients at the end of treatment and in 24 % of the patients at 6-month follow-up. At treatment completion (12 months), culture was negative in 21 patients (84 %) and in 18 (72 %) at follow-up. It was not possible to establish any clinical or mycological statistical differences between groups (p > 0.05). Global medical evaluation upon treatment completion revealed that one patient (4 %) presented complete cure, 8 (32 %) presented partial cure, 16 (64 %) presented therapeutic failure. At the end of follow-up period, 6 patients (24 %) were considered to have recurrence/reinfection.


The results obtained at the 6-month period of follow-up showed marked improvement (96 % of clinical improvement and 72 % of negative culture) of the patients treated for onychomycosis caused by Neoscytalidium in the three tested groups with no statistical differences between them. Multicentric studies with greater number of patients enrolled are necessary to confirm these results.


Onychomycosis Neoscytalidium Scytalidium Terbinafine Ciclopirox 


Conflict of interest

Authors have no relationship with industry for this study.


  1. 1.
    Ellis DH, Marley JE, Watson AB, Williams TG. Significance of non-dermatophyte moulds and yeast in onychomycosis. Dermatology. 1997;194:40–2.PubMedCrossRefGoogle Scholar
  2. 2.
    Gupta AK, Jain HC, Lynde CW, MacDonald P, et al. Prevalence and epidemiology of onychomycosis in patients visiting physicians offices: a multicenter Canadian survey of 15,000 patients. J Am Acad Dermatol. 2000;43:244–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Ellis DH, Watson AB, Marley JE, Williams TG. Non-dermatophyte in onychomycosis of the toenails. Br J Dermatol. 1997;136:490–3.PubMedCrossRefGoogle Scholar
  4. 4.
    Pavlovic MD, Bulajic N, Huntley AC. Great toenail onychomycosis caused by Syncephalastrum racemosum. Dermatol Online J. 2006;12(1) From Dermatology Online Journal Accessed: 03 Feb 2006.
  5. 5.
    Lacroix C, Kac G, Dubertret L, Morel P, et al. Scytalidiosis in Paris. France J Am Acad Dermatol. 2003;48:852–6.CrossRefGoogle Scholar
  6. 6.
    Araújo AJG, Bastos OMP, Sousa MAJ, Oliveira JC. Occurrence of onychomycosis among patients attended in dermatology offices in the city of Rio de Janeiro. An Bras Dermatol. 2003;78(3):445–55.CrossRefGoogle Scholar
  7. 7.
    Crous PW, Slippers B, Wingfield MJ, Rheeder J, et al. Phylogenetic lineages in the Botryosphaeriaceae. Stud Mycol. 2006;55:235–53.PubMedCrossRefGoogle Scholar
  8. 8.
    Madrid H, Ruíz-Cendoya M, Cano J, Stchigel A, Orofino R, Guarro J. Genotyping and in vitro antifungal susceptibility of Neoscytalidium dimidiatum isolates from different origins. Int J Antimicrob Agents. 2009;34:351–4.PubMedCrossRefGoogle Scholar
  9. 9.
    Tosti A, Peraccini BM, Lorenzi S. Onychomycosis caused by non-dermatophytic molds: clinical features and response to treatment of 59 cases. J Am Acad Dermatol. 2000;42:217–24.PubMedCrossRefGoogle Scholar
  10. 10.
    Elewski BE, Greer DL. Hendersonula toruloidea and Scytalidium hyalinum. Arch Dermatol. 1991;127:1041–4.PubMedCrossRefGoogle Scholar
  11. 11.
    Gupta AK, Drummond-Main C, Cooper EA, Brintnell W, Piraccini BM, Tosti A. Systematic review of non-dermatophyte mold onychomycosis: diagnosis, clinical types, epidemiology, and treatment. J Am Acad Dermatol. 2012;66:494–502.PubMedCrossRefGoogle Scholar
  12. 12.
    Di Chiachio N, Kadunc BV, De Almeida ART, Madeira CL. Nail abrasion. J Cosmet Dermatol. 2003;2:150–2.CrossRefGoogle Scholar
  13. 13.
    Cursi IB, Freitas LBCR, Neves MLP, Silva IC, Orofino-Costa R. Onychomycosis due to Scytalidium spp.: a clinical and epidemiologic study at a University Hospital in Rio de Janeiro. An Bras Dermatol. 2011;86(4):689–93.PubMedCrossRefGoogle Scholar
  14. 14.
    Belloeuf L, Boisseau-Garsaud AM, et al. Nail disease due to Scytalidium in martinique (French West Indies). Ann Dermatol Venereol. 2004;13:245–9.CrossRefGoogle Scholar
  15. 15.
    Baran R, Kaoukhov A. Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy. J Eur Acad Dermatol Venereol. 2004;19:21–9.CrossRefGoogle Scholar
  16. 16.
    Simonnet C, Berger F, Gantier JC. Epidemiology of superficial fungal diseases in French Guiana: a three-year retrospective analysis. Med Mycol. 2011;49:608–11.PubMedGoogle Scholar
  17. 17.
    Lacroix C, de Chauvin MF. In vitro activity of amphotericin B, itraconazole, voriconazole, posaconazole, caspofungin and terbinafina against Scytalidium dimidiatum and Scytalidium hyalinum clinical isolates. J Antimicrob Chemother. 2008;61:835–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Dunand J, Paugam A. In vitro susceptibility of isolates of Scytalidium spp. from superficial lesions against posaconazole. Pathol Biol (Paris). 2008;56:268–71.CrossRefGoogle Scholar
  19. 19.
    Elinav H, Izhar U, Benenson S, Admon D, Hidalgo-Grass C, Polacheck I, Korem M. Invasive Scytalidium dimidiatum infection in an immunocompetent adult. J Clin Microbiol. 2009;47(4):1259–63.PubMedCrossRefGoogle Scholar
  20. 20.
    Ikram A, Hussain W, Satti ML, Wiqar MA. Invasive infection in a young immunocompetent soldier caused by Scytalidium dimidiatum. J Coll Physicians Surg Pak. 2009;19(1):64–6.PubMedGoogle Scholar
  21. 21.
    Ruíz-Cendoya M, Madrid H, Pastor FJ, Mayayo E, Mariné M, Guarro J. Development of murine models of disseminated infection by Neoscytalidium dimidiatum. Med Mycol. 2010;48:681–6.PubMedCrossRefGoogle Scholar
  22. 22.
    Gupta AK, Ryder JE, Summerbell RC. The diagnosis of non-dermatophyte mold onychomycosis. Int J Dermatol. 2003;42:272–3.PubMedCrossRefGoogle Scholar
  23. 23.
    Arrese JE, Piérard-Franchimont C, Piérard GE. Scytalidium dimidiatum melanonychia and scaly plantar skin in four patients from the Maghreb: imported disease or outbreak in a Belgian mosque? Dermatology. 2001;202:183–5.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2012

Authors and Affiliations

  • Ígor B. Cursi
    • 1
  • Roberta Teixeira Silva
    • 1
  • Isabella Brasil Succi
    • 1
  • Andréa R. Bernardes-Engemann
    • 1
  • Rosane Orofino-Costa
    • 1
    Email author
  1. 1.Dermatology Department, Hospital Universitário Pedro ErnestoUniversidade do Estado do Rio de JaneiroRio de JaneiroBrazil

Personalised recommendations